Transparency Market Research Report Added "Anti-Tumor Drugs Market" to its database.
Albany, NY -- (SBWIRE) -- 03/28/2016 -- A new research report by Transparency Market Research (TMR) presents a comprehensive overview as well as an unbiased analysis of the global market for anti-tumor drugs. The study is titled "Anti-Tumor Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019."
A tumor, also known as a neoplasm, is caused by an unusual proliferation of tissues. It is broadly classified as a benign tumor and a malignant tumor. A malignant tumor is cancerous in nature while a benign tumor possesses the potential to turn into a malignant one. The increasing incidence of the malignant tumor is propelling the demand for anti-tumor drugs in the global arena. According to the WHO, by the end of 2025, the number of patients suffering from cancer would reach 15 million globally. Going by the prediction, the worldwide anti-tumor drugs market is likely to witness exponentially increasing demand for these drugs over the next few years.
In addition to this, governments and various non-governmental organizations in several economies are getting concerned over the alarming rate of mortality due to cancer across the world and have taken various initiatives to encourage the development of anti-tumor as well as anti-cancer drugs. This factor, along with the increased government funding for research and development activities in this field, also leads to the significant growth of the global anti-tumor drugs in the near future.
According to the report, the future of the global anti-tumor market looks thriving. However, various side-effects such as hair loss, weakness, nausea, allergies, and other dermatological side effects of these drugs are likely to restrict the market's growth in the coming years.
Anti-tumor drugs help in limiting the growth of tumor cells by regulating the level of hormones in these cells. Various anti-tumor drugs mentioned in this market report are idarucicin, daunorubicin, citomycin D, doxorubicin, epirubicin, bleomycin, mitoxantrone, and mitomycin.
Additionally, alkaloids, used as anti-tumors drugs, such as irinotecan, etoposide, topotecan, vinorelbine, vinblastine, streptozocin, chlorambucil, ifosfamide, cyclophosphamide, melphalan, paclitaxel, vincristine, bendamustine, temozolomide, dacarbazine, busulfan, procarbazine, carmustine, and docetaxel, are also mentioned in this study.
Brochure Download: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1421
The report also maps the competitive landscape of the global anti-tumor drugs market by assessing the company profiles of the key market players. As per the research study, Ionis Pharmaceuticals, Gilead Sciences, and Bristol-Myers Squibb are leading the worldwide market for anti-tumor drugs.
The main objective of this research is to provide a clear picture of the global anti-tumor drugs market to participants, stakeholders, and consultants and assist them in making crucial strategies for the further expansion of their businesses.